The US FDA has recently approved ‘Pretomanid’ a new drug for treating hard-to-treat drug-resistant Tuberculosis (TB) that makes the treatment regimen shorter and simpler. Pretomanid was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) as a part of 3 drugs i.e. BEDAQUILINE, PRETOMANID AND LINEZOLID – collectively referred to as the BPaL regimen. Tuberculosis has the highest mortality rate with 1.6 million deaths a year, out of which, 500,000 patients suffer from drug-resistant strains of the disease.
Multidrug-resistant TB (MDR TB) and extensively drug-resistant TB (XDR TB) are the major public health threats because of limited treatment options. And therefore, new treatments are important to meet patient’s national and global health needs. Drug Information Study Population The trial population involved 109 patients diagnosed with XDR-TB…
